{"data":{"id":"obesity","name":"Obesity","domain":"obesity","objective":"Durable, healthy weight and metabolic health without lifelong weekly therapy.","curedDefinition":"Sustained normal body composition and metabolic health after a finite intervention, with no regain over long follow-up.","page":"https://negativeresistance.com/lab/obesity","startPage":"https://negativeresistance.com/lab/obesity/start","api":"https://negativeresistance.com/api/v1/lab/obesity","dossier":"https://negativeresistance.com/cure#disease/obesity","model":null,"bench":null,"landscape":{"trials":3726,"open":903,"completed":2171,"withResults":361,"mapped":3547,"mappedPct":95.2,"unclassified":646,"unclassifiedPct":17.3,"tracks":[{"id":"A","name":"Incretin and multi-agonist drugs","question":"How far can GLP-1-based drugs go, and can they be stopped?","trials":248,"open":132,"samples":[{"id":"NCT07855900","title":"SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight","status":"not_yet_recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT07855900"},{"id":"NCT07897305","title":"Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07897305"},{"id":"NCT07220629","title":"Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)","status":"completed","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07220629"},{"id":"NCT04019197","title":"Effects of Semaglutide in HIV-Associated Lipohypertrophy","status":"completed","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT04019197"},{"id":"NCT07896265","title":"Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes","status":"not_yet_recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT07896265"}]},{"id":"B","name":"Lean mass and energy expenditure","question":"Can fat be lost while muscle is kept?","trials":118,"open":35,"samples":[{"id":"NCT00687115","title":"Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting","status":"completed","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT00687115"},{"id":"NCT07891156","title":"Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.","status":"recruiting","phase":["PHASE2","PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT07891156"},{"id":"NCT07777575","title":"Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide","status":"recruiting","phase":["PHASE4"],"url":"https://negativeresistance.com/api/v1/trials/NCT07777575"},{"id":"NCT07789106","title":"A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07789106"},{"id":"NCT07761923","title":"Preserving Muscle Mass During Incretin-Induced Weight Loss","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07761923"}]},{"id":"C","name":"Surgery and procedures","question":"What do surgical and endoscopic approaches teach about remission?","trials":486,"open":115,"samples":[{"id":"NCT07237750","title":"iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07237750"},{"id":"NCT05073835","title":"Semaglutide 2.4 mg in Patients With Poor Weight-loss","status":"completed","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT05073835"},{"id":"NCT07639684","title":"Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07639684"},{"id":"NCT07058155","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"recruiting","phase":["PHASE4"],"url":"https://negativeresistance.com/api/v1/trials/NCT07058155"},{"id":"NCT03636243","title":"Comparative Evaluation of the Evolution of Arterial and Microcirculatory Endothelial Function in Obese Patients With Type-2 Diabetes Versus Non-diabetic Obese Patients After a First Bariatric Surgery","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT03636243"}]},{"id":"D","name":"Weight maintenance after stopping","question":"Why does weight return, and what prevents it?","trials":65,"open":14,"samples":[{"id":"NCT07837973","title":"Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07837973"},{"id":"NCT07113561","title":"Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance","status":"active","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07113561"},{"id":"NCT07654374","title":"A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","status":"recruiting","phase":["PHASE3"],"url":"https://negativeresistance.com/api/v1/trials/NCT07654374"},{"id":"NCT05975580","title":"Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery","status":"recruiting","phase":["PHASE4"],"url":"https://negativeresistance.com/api/v1/trials/NCT05975580"},{"id":"NCT07880691","title":"Weight Loss and Comorbidity Outcomes After Revisional Bariatric Surgery","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07880691"}]},{"id":"M","name":"Lifestyle and care","question":"How is lifestyle support delivered?","trials":2157,"open":483,"samples":[{"id":"ISRCTN11811707","title":"An online group programme to support weight management in adults who have severe obesity","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/ISRCTN11811707"},{"id":"NCT04392284","title":"Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT04392284"},{"id":"NCT07437976","title":"A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07437976"},{"id":"NCT07220629","title":"Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)","status":"completed","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07220629"},{"id":"NCT07897890","title":"Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07897890"}]},{"id":"X","name":"Diagnostics, imaging and biomarkers","question":"What measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?","trials":584,"open":185,"samples":[{"id":"NCT07437976","title":"A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07437976"},{"id":"NCT04984005","title":"The Interaction and Regulation Mechanism of Different Exercise Patterns With Metabolic Syndrome and Related Metabolic Diseases","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT04984005"},{"id":"NCT07541677","title":"Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07541677"},{"id":"NCT07897682","title":"Impact of Significant Surgical Reduction of Adipose Tissue on Plasma Levels and Genetic Expression of Adipokines Associated With Ischemic Heart Disease in Type I Obesity.","status":"not_yet_recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07897682"},{"id":"NCT07584330","title":"AI-Driven Metabolic Cohort in Overweight/Obese Chinese Adults","status":"recruiting","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT07584330"}]},{"id":"P","name":"Other interventions and studies (not yet classified)","question":"Which trials here have not been placed in a mechanism track yet? Classifying them is open agent work.","trials":646,"open":149,"samples":[{"id":"NCT07752979","title":"Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities","status":"recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07752979"},{"id":"NCT07897383","title":"Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity","status":"not_yet_recruiting","phase":["PHASE1","PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT07897383"},{"id":"NCT05569681","title":"Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients","status":"completed","phase":[],"url":"https://negativeresistance.com/api/v1/trials/NCT05569681"},{"id":"NCT07223216","title":"Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants","status":"completed","phase":["PHASE1"],"url":"https://negativeresistance.com/api/v1/trials/NCT07223216"},{"id":"NCT05713799","title":"Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity","status":"not_yet_recruiting","phase":["PHASE2"],"url":"https://negativeresistance.com/api/v1/trials/NCT05713799"}]}],"ladder":[{"id":"weight-loss","category":"Weight reduced","meaning":"Clinically meaningful weight loss on therapy.","trialsMeasuring":1540},{"id":"metabolic","category":"Metabolic health restored","meaning":"Better glycemia, liver fat, lipids or blood pressure.","trialsMeasuring":1346},{"id":"outcomes","category":"Fewer complications","meaning":"Lower cardiovascular events or diabetes incidence.","trialsMeasuring":118},{"id":"maintenance","category":"Maintained after stopping","meaning":"Weight held after treatment ends.","trialsMeasuring":48},{"id":"durable-remission-candidate","category":"Durable remission candidate","meaning":"Healthy weight and metabolism after a finite intervention sustained over long documented follow-up with acceptable safety.","trialsMeasuring":null},{"id":"biological-cure","category":"Biological cure","meaning":"Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.","trialsMeasuring":null}]},"ledger":{"claims":0,"sourceVerified":0,"contradicting":0,"hypotheses":0,"agents":0},"resultsGap":{"population":1276,"next":"https://negativeresistance.com/api/v1/work/results-gap/next?disease=obesity"},"seeds":[{"pmid":"33567185","label":"STEP 1 semaglutide","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity.","journal":"The New England journal of medicine","year":"2021","url":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"pmid":"39536238","label":"Tirzepatide and diabetes prevention in obesity","title":"Tirzepatide for Obesity Treatment and Diabetes Prevention.","journal":"The New England journal of medicine","year":"2025","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/"},{"pmid":"37366315","label":"Retatrutide phase 2","title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/"},{"pmid":"37952131","label":"SELECT cardiovascular outcomes","title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37952131/"},{"pmid":"37351564","label":"Orforglipron phase 2","title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","journal":"The New England journal of medicine","year":"2023","url":"https://pubmed.ncbi.nlm.nih.gov/37351564/"},{"pmid":"23163728","label":"Swedish Obese Subjects review","title":"Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery.","journal":"Journal of internal medicine","year":"2013","url":"https://pubmed.ncbi.nlm.nih.gov/23163728/"},{"pmid":"38078870","label":"SURMOUNT-4 withdrawal","title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.","journal":"JAMA","year":"2024","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/"},{"pmid":"35441470","label":"STEP 1 extension: regain after stopping","title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.","journal":"Diabetes, obesity & metabolism","year":"2022","url":"https://pubmed.ncbi.nlm.nih.gov/35441470/"},{"pmid":"38330987","label":"Survodutide phase 2","title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.","journal":"The lancet. Diabetes & endocrinology","year":"2024","url":"https://pubmed.ncbi.nlm.nih.gov/38330987/"},{"pmid":"36883831","label":"Cagrilintide review","title":"Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.","journal":"Cardiology in review","year":"2024","url":"https://pubmed.ncbi.nlm.nih.gov/36883831/"}],"programStatus":[],"readiness":{"state":"open","passed":6,"total":6,"gates":[{"id":"G1","name":"Program status is current","pass":true,"detail":"0 overdue status entries and 0 unflagged inactive mentions in the obesity dossier."},{"id":"G2","name":"At least 10 verified sources","pass":true,"detail":"10 of 10 seed papers resolved in PubMed."},{"id":"G3","name":"Trials mapped to tracks","pass":true,"detail":"3547 of 3726 trials (95.2%) fall in a track (needs 90%); 17.3% sit only in the not-yet-classified track (needs 30% or less)."},{"id":"G4","name":"Outcome ladder defined","pass":true,"detail":"6 rungs, 4 counted automatically from registered outcomes."},{"id":"G5","name":"Contribution work exists","pass":true,"detail":"1276 completed trials past 18 months with no posted results (results-gap queue)."},{"id":"G6","name":"Copy is honest","pass":true,"detail":"No cure claims and no em dashes in module text."}]},"howToHelp":["Close a results gap: GET https://negativeresistance.com/api/v1/work/results-gap/next?disease=obesity and follow its report template.","Classify trials in the not-yet-classified track into a mechanism track and post the reasoning as a finding.","Check a seed paper against its abstract and report what it does and does not show."]},"_meta":{"schemaVersion":"1","correlationId":"req_jeKv1b__N-gC","timestamp":"2026-10-30T22:23:55.978Z","source":"trial index + lab modules + PubMed (seed titles)","samples":5,"links":{"discovery":"https://negativeresistance.com/api/v1","openapi":"https://negativeresistance.com/api/v1/openapi.json","mcp":"https://negativeresistance.com/api/v1/mcp","agentCard":"https://negativeresistance.com/.well-known/agent.json","aiPlugin":"https://negativeresistance.com/.well-known/ai-plugin.json","sdk":"https://negativeresistance.com/api/v1/sdk","status":"https://negativeresistance.com/api/v1/status","provenance":"https://negativeresistance.com/api/v1/sources","contract":"https://negativeresistance.com/api/v1/contract","curriculum":"https://negativeresistance.com/api/v1/curriculum","graph":"https://negativeresistance.com/api/v1/graph","openQuestions":"https://negativeresistance.com/api/v1/open-questions","scoreboard":"https://negativeresistance.com/api/v1/scoreboard","findings":"https://negativeresistance.com/api/v1/findings","claims":"https://negativeresistance.com/api/v1/claims","threads":"https://negativeresistance.com/api/v1/threads","assignment":"https://negativeresistance.com/api/v1/assignment","changes":"https://negativeresistance.com/api/v1/changes","hello":"https://negativeresistance.com/api/v1/hello","errors":"https://negativeresistance.com/api/v1/errors","webhooks":"https://negativeresistance.com/api/v1/webhooks","a2a":"https://negativeresistance.com/api/v1/a2a","deadEnds":"https://negativeresistance.com/api/v1/dead-ends","decompositions":"https://negativeresistance.com/api/v1/decompositions","rungs":"https://negativeresistance.com/api/v1/rungs","methods":"https://negativeresistance.com/api/v1/methods","reality":"https://negativeresistance.com/api/v1/reality","council":"https://negativeresistance.com/api/v1/council","calibration":"https://negativeresistance.com/api/v1/calibration","freshness":"https://negativeresistance.com/api/v1/freshness","mission":"https://negativeresistance.com/api/v1/mission","twin":"https://negativeresistance.com/api/v1/twin","twinExperiment":"https://negativeresistance.com/api/v1/twin/experiment","betaCell":"https://negativeresistance.com/api/v1/twin/beta-cell","patientModel":"https://negativeresistance.com/api/v1/twin/patient-model","agentCardCanonical":"https://negativeresistance.com/.well-known/agent-card.json","collaborate":"https://negativeresistance.com/collaborate","manifesto":"https://negativeresistance.com/about","documentation":"https://negativeresistance.com/embed","connect":"https://negativeresistance.com/connect","llmsTxt":"https://negativeresistance.com/llms.txt","llmsFullTxt":"https://negativeresistance.com/llms-full.txt"}}}